Metraipolis › archive › dc_262fbb8cdf05

Apimostinel — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Apimostinel
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-09T16:49:23.507Z
SHA-256 of the archived text
cea7ced452355736ed6a1099b61063b3507115936c3b63d40a687ce5ee0c2d97
Stable URL of this page
https://metraipolis.com/documento/dc_262fbb8cdf05

How to cite

Apimostinel — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Apimostinel (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_262fbb8cdf05 (Metraipolis archive dc_262fbb8cdf05, sha256 cea7ced452355736ed6a1099b61063b3507115936c3b63d40a687ce5ee0c2d97)
BibTeX
@misc{dc262fbb8cdf05,
  title = {Apimostinel — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Apimostinel},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_262fbb8cdf05; sha256 cea7ced452355736ed6a1099b61063b3507115936c3b63d40a687ce5ee0c2d97},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Apimostinel. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Apimostinel (GATE-202, formerly NRX-1074) is an investigational antidepressant, acting as a novel and selective modulator of the NMDA receptor. It is currently under development for the acute treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Naurex and Allergan. As of February 2015, an intravenous formulation of apimostinel has completed a phase IIa clinical trial for MDD. Similar to rapastinel (GLYX-13), its mechanism of action acts through a unique binding site on the NMDA receptor, independent of the glycine site, to modulate receptor activity and enhance NMDAR-mediated synaptic plasticity. However, apimostinel is 1000-fold more potent in vitro and is intended as an improved, follow-up drug to rapastinel. Similar to rapastinel, apimostinel is an amidated tetrapeptide, but has been structurally modified, via the addition of a benzyl group, to enhance its metabolic stability and pharmacokinetic profile. The drug has shown rapid and potent antidepressant effects in pre-clinical models of depression. In addition, similarly to rapastinel, it is well tolerated and lacks the hallucinosis-like psychotomimetic effects of NMDA receptor antagonists such as ketamine.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Apimostinel» — https://en.wikipedia.org/wiki/Apimostinel
Wikidata Q27290341: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q27290341
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Apimostinel?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1298107639, consultata il 2026-11-09T16:46:20.083Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 60269c544653091fbb36c1b685241dc54e845c9677eab799d6a13931ce4af7d2